ICH Suggests Antihypertensive Drug Trials Add Focus On Systolic Measures
Clinical trials for new antihypertensive drugs need an increased focus on systolic blood pressure reduction, an International Conference on Harmonization draft guidance on antihypertensive drug development states.
You may also be interested in...
The International Conference on Harmonization's clinical trial control groups guidance should offer more specific advice on how to select a control group acceptable to all ICH regulators, AstraZeneca said in recent comments to FDA.
Merck's defense of its antihypertensive franchise following the launch of Bristol-Myers Squibb's Vanlev will include an emphasis on the efficacy of its angiotensin II/diuretic combination product Hyzaar.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011